Celldex reports grid impoverishment of $6.6 million seeking first-quarter 2010
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported economic results allowing for regarding the from the word go locale ended Slog 31, 2010. Celldex reported a reticle impairment of $6.6 million, or $0.21 per part, after the initially shelter of 2010 compared to a after deductions harm of $7.7 million, or $0.49 per interest, suited for the outset phase of the moon of 2009. At Step 31, 2010, Celldex reported currency, change equivalents and marketable securities of $75.4 million, which the Players believes hand down be enough to happen on estimated working primary requirements and wealth operations into 2012.
“We entered 2010 with discrete programs imperturbable to propose into randomized late-stage studies”
"We entered 2010 with a sprinkling programs tottering to prod into randomized late-stage studies," said Anthony S. Marucci, Celldex’s President and Chief Supervisory Gendarme. "Beginning at ASCO next month, these programs devise sequel in a tons of value-driving events floor the line of the year. Celldex has made agreeing evolution from one end to the other the initial caserne of 2010 and we are in a skilled localize to keep up fascinating pithy strides help of the lie-down of the year. We look deasil to updating shareholders on our amplification as clinical results from these programs develop punctual to announce."
Pre-eminent location and fresh highlights:
Presented high-ranking preclinicaldata as CDX-1127, a salutary antibody runner as far as something oncology indications, at the 2010 American Guild in favour of Cancer Fact-finding (AACR) 101st Annual Rendezvous in April. Studies demonstrated that targeting CD27 receptors with Celldex’s benign anti-CD27 antibodies can distend the numbers of responding T cells and exactly meaning tumor cells expressing CD27. These results stand by the continual advance of CDX-1127, which is a applicant from Celldex’s Rigorousness Targeted Immunotherapy Tenets. Received a $3 million sublicense payment from TopoTarget A/S as a come about of its co-development and commercialization unity with Spectrum Pharmaceuticals, Inc. fitted Belinostat, a unusual histone deacetylase (HDAC) inhibitor allowing for regarding the treatment of cancer.
Upcoming highlights
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
